Sentien is restoring balance to the immune system by enabling sustained, dynamic secreting of therapeutic molecules for systemic inflammation.
Location: United States, Massachusetts, Lexington
Total raised: $12M
Investors 2
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Chiesi Ven... | chiesivent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.04.2017 | Series A | $12M | - |
Mentions in press and media 4
| Date | Title | Description |
| 02.09.2021 | Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis | LEXINGTON, Mass. (PRWEB) September 02, 2021 Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced Research and Developme... |
| 30.03.2021 | Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 | LEXINGTON , Mass. (PRWEB) March 30, 2021 Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort in its Phase 1/2 stu... |
| 04.04.2017 | Sentien Biotechnologies Raises $12M in Series A Funding | Sentien Biotechnologies, Inc., a Cambridge, MA-based clinical-stage biotechnology company developing novel approaches to cell therapy, closed a $12m Series A funding. The round was co-led by Boehringer Ingelheim Venture Fund USA, Inc. (BIVF... |
| 07.08.2015 | Sentien Biotechnologies Raises Series A Funding Round | Sentien Biotechnologies, Inc., a Medford, MA-based regenerative medicine company developing cell based therapies for acute organ failure, raised a Series A funding round of undisclosed amount. The investment was led by Boehringer Ingelheim ... |